Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Treatment benefits of simultaneous initiation and combination therapy with the nonsteroidal mineralocorticoid receptor antagonist finerenone and a sodium–glucose cotransporter 2 inhibitor (SGLT2i) in reducing urinary albumin-to-creatinine ratio (UACR) have been reported in the CONFIDENCE trial. We evaluated the benefits and safety profile of combination therapy with finerenone and an SGLT2i in participants enrolled in Asia.
The CONFIDENCE trial enrolled adults with chronic kidney disease and type 2 diabetes with a UACR of ≥100 to ≤5000 mg/g and on a renin–angiotensin system inhibitor. Participants were randomized 1:1:1 to once-daily finerenone (10 or 20 mg) plus empagliflozin (10 mg), finerenone (10 or 20 mg) plus placebo, or empagliflozin (10 mg) plus placebo. In a subgroup analysis, treatment effects on the primary endpoint of relative change in UACR from baseline at day 180 were assessed for Asian participants.
In CONFIDENCE, among 360 participants (45%) enrolled from Asia, change in UACR from baseline (95% CI) at day 180 with combination therapy was −30% (−44%, −11%) vs finerenone alone and −34% (−47%, −16%) vs empagliflozin alone; Table). The proportion of Asian participants with any treatment-emergent hyperkalemia adverse events (AEs) was 10.7% for those receiving combination therapy, 13.8% for finerenone alone, and 4.8% for empagliflozin alone. No treatment-emergent hyperkalemia AEs led to hospitalization, permanent discontinuation of study drug, or death. These findings are consistent with those for the overall study population.
Simultaneous initiation of finerenone and an SGLT2i was effective and well-tolerated among the nearly half of participants in CONFIDENCE who were enrolled from Asia.
This abstract was also submitted to the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD).
